Pursuant to clause 33 of the Listing Obligations and Disclosure Requirements Regulations, 2015 (LODR), GlaxoSmithKline Pharmaceuticals has informed that a meeting of the Board of Directors of the Company will be held on Tuesday, 18th May 2021, to consider amongst other things, approval of audited financial results (Standalone & Consolidated) for the quarter / year ended 31st March 2021 and to recommend dividend, if any, on the equity shares of the Company.
The above information is a part of company’s filings submitted to BSE.
